Continuing immune checkpoint inhibitors beyond progression versus switching to non-ICI therapy in advanced gastric cancer: a real-world study
Guangxi Wang, Xiaonan Lu, Yunmei Wang, Xiang Wang, Ruoxuan Wang, Jinyu Jia · 2026
Read Continuing immune checkpoint inhibitors beyond progression versus switching to non-ICI therapy in advanced gastric cancer: a real-world study by Guangxi Wang, Xiaonan Lu, Yunmei Wang, Xiang Wang, Ruoxuan Wang, Jinyu Jia (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13272025.txt.
Description
Guangxi Wang and coauthors compare in 2026 two second-line strategies after immunotherapy-based treatment stops working in advanced stomach cancer. Doctors can keep the immune drug going past progression or switch to a regimen without it. No standard choice exists, so real-world outcomes carry weight.
The single-center study covered 169 patients whose cancer grew on first-line immune drug plus chemotherapy. Those who continued the immune drug lived longer without progression and longer overall than those who switched away. The advantage survived statistical adjustment and patient matching, and it was clearest in patients who had responded well the first time. Side effects stayed manageable.
Catalog record
| CREATOR | Guangxi Wang, Xiaonan Lu, Yunmei Wang, Xiang Wang, Ruoxuan Wang, Jinyu Jia |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |